Baxter to Provide Fill/Finish and Packaging Services for Moderna’s COVID-19 Vaccine

News
Article

Manufacturing of the vaccine will take place at Baxter’s fill/finish sterile manufacturing facilities located in Bloomington, IN.

Baxter and Moderna announced on March 8, 2021 that they have entered into an agreement where Baxter’s contract manufacturing organization, Baxter BioPharma Solutions, will provide fill/finish sterile manufacturing services and supply packaging for 60–90 million doses of the Moderna COVID-19 vaccine in 2021.

Under the terms of the agreement, manufacturing of the vaccine will take place at Baxter’s fill/finish sterile manufacturing facilities located in Bloomington, IN, Baxter said in a company press release. Additional details of the partnership were not disclosed.

“We have seen a remarkable demonstration of scientific and health care expertise in the effort to develop vaccines for COVID-19,” said Marie Keeley, vice-president, Baxter BioPharma Solutions, in the press release. “Baxter is honored to provide our deep expertise in vaccine manufacturing to help partners like Moderna bolster the supply of their vaccine.”

“We welcome the opportunity to work with Baxter BioPharma Solutions on fill/finish manufacturing for the Moderna COVID-19 vaccine in the [United States],” added Juan Andres, Moderna’s chief technical operations and quality officer, in the press release. “This additional production will help us continue to scale up our manufacturing capacity in the [US].”

Source: Baxter

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content